GlassScriptPhysician profile
Melissa A Acquazzino
NPI 1871722413
$251.13
in general payments reported to CMS, 2019-2025
7 companies · $62.68 in 2025
The $62.68 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.23 · 2022: $50.30 · 2024: $48.92 · 2025: $62.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $62.94 | 2019 | |
| Novo Nordisk INC | $53.90 | 2022-2025 | Alhemo |
| Y-Mabs Therapeutics, INC. | $33.93 | 2024 | Danyelza |
| Genzyme Corporation | $31.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.68 | 2025 | Koselugo |
| Sobi, INC | $26.29 | 2019 | |
| Genentech USA, INC. | $14.99 | 2024 | Hemlibra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Acquazzino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.